Cardiovascular Diabetology

Papers
(The H4-Index of Cardiovascular Diabetology is 53. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin323
Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations279
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin213
Triglyceride–glucose index and the incidence of atherosclerotic cardiovascular diseases: a meta-analysis of cohort studies189
Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC)138
Risk for cardiovascular disease associated with metabolic syndrome and its components: a 13-year prospective study in the RIVANA cohort134
Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management131
GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs131
Relationship between the triglyceride-glucose index and risk of cardiovascular diseases and mortality in the general population: a systematic review and meta-analysis128
CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries122
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction115
Triglyceride–glucose index is associated with the risk of myocardial infarction: an 11-year prospective study in the Kailuan cohort107
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis107
Stronger association of triglyceride glucose index than the HOMA-IR with arterial stiffness in patients with type 2 diabetes: a real-world single-centre study105
Diabetes and Covid-19 among hospitalized patients in Saudi Arabia: a single-centre retrospective study104
Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease100
Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry100
Association between triglyceride-glucose index and risk of arterial stiffness: a cohort study97
Comprehensive elaboration of glycemic variability in diabetic macrovascular and microvascular complications90
Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analy86
Triglyceride-glucose index and the risk of stroke and its subtypes in the general population: an 11-year follow-up84
Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study84
Proteomics of fibrin amyloid microclots in long COVID/post-acute sequelae of COVID-19 (PASC) shows many entrapped pro-inflammatory molecules that may also contribute to a failed fibrinolytic system82
Direct cardiac effects of SGLT2 inhibitors80
The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs80
Association of TyG index and TG/HDL-C ratio with arterial stiffness progression in a non-normotensive population79
Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle‐stimulated endothelial senescence and dysfunction: protective effect of gliflozins76
Change in triglyceride-glucose index predicts the risk of cardiovascular disease in the general population: a prospective cohort study75
Triglyceride-glucose index and triglyceride to high-density lipoprotein cholesterol ratio as potential cardiovascular disease risk factors: an analysis of UK biobank data74
The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management74
Low-grade inflammation as a risk factor for cardiovascular events and all-cause mortality in patients with type 2 diabetes74
Hyperglycemia, inflammatory response and infarct size in obstructive acute myocardial infarction and MINOCA74
Glycated ACE2 receptor in diabetes: open door for SARS-COV-2 entry in cardiomyocyte72
Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy69
Triglyceride-glucose index is associated with in-stent restenosis in patients with acute coronary syndrome after percutaneous coronary intervention with drug-eluting stents69
SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs68
Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF67
Association between the triglyceride–glucose index and severity of coronary artery disease65
Prognostic value of triglyceride glucose (TyG) index in patients with acute decompensated heart failure65
The triglyceride-glucose index is a predictor for cardiovascular and all-cause mortality in CVD patients with diabetes or pre-diabetes: evidence from NHANES 2001–201864
Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention64
Variability of risk factors and diabetes complications62
MicroRNAs and long non-coding RNAs in the pathophysiological processes of diabetic cardiomyopathy: emerging biomarkers and potential therapeutics61
Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis61
TyG index is positively associated with risk of CHD and coronary atherosclerosis severity among NAFLD patients59
The role of remnant cholesterol beyond low-density lipoprotein cholesterol in diabetes mellitus59
Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug59
Triglyceride-glucose index and the risk of heart failure: Evidence from two large cohorts and a mendelian randomization analysis57
Autonomic nervous system activity changes in patients with hypertension and overweight: role and therapeutic implications57
Triglyceride-glucose index variability and incident cardiovascular disease: a prospective cohort study57
Atherogenic index of plasma is associated with major adverse cardiovascular events in patients with type 2 diabetes mellitus56
Gender difference in the association between TyG index and subclinical atherosclerosis: results from the I-Lan Longitudinal Aging Study56
Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk54
Cumulative triglyceride-glucose index is a risk for CVD: a prospective cohort study53
Dapagliflozin: a sodium–glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling53
The impact of triglyceride-glucose index on ischemic stroke: a systematic review and meta-analysis53
0.10562086105347